CureVac N.V. Overview
Pro stress-test →CureVac is a multinational biotech company focused on mRNA-based medicines, including oncology immunotherapies and prophylactic vaccines. Founded in 2000, CureVac has more than two decades of experience in developing, optimizing, and manufacturing mRNA for medical applications. As of January 2026, the company is no longer independent following BioNTech becoming the sole owner of all CureVac business operations through a completed reorganization.
Strategic Profile
Pro stress-test →Its proprietary platforms use optimized mRNA as a data carrier to instruct the human body to produce its own proteins that can help fight a broad range of diseases. The company has collaborations including a licensing agreement with GSK for mRNA vaccine candidates, and agreements with BioNTech and Pfizer related to patent litigation resolution and licensing of certain mRNA-based COVID-19 and influenza products.
Competitive Landscape
Pro stress-test →The company faces significant competitive risks against both established products and in-development candidates. Key competitors in the mRNA therapeutics space include BioNTech, Moderna, and Arcturus Therapeutics. CureVac's competitive position has been challenged by the limited efficacy of its COVID-19 vaccine candidate and is now integrated within the BioNTech organization.
Industry Context
CureVac N.V. operates in Biopharmaceutical / mRNA Therapeutics.
Key facts
Founded: 2000 · Headquarters: Tübingen, Germany